Incidence and prognostic factors of breast cancer diagnosed within and outside of the organised screening program in the department of Loire-Atlantique (1991-2002);Incidence et facteurs pronostiques des cancers du sein découverts au cours et en dehors du programme de dépistage organisé en Loire-Atlantique (1991-2002)

Revue d'Epidemiologie et de Sante Publique

Volumn 56, Issue 1, 2008, Pages 41-49

  Molinie F ^a   Billon Delacour, S ^a   Allioux, C ^b   Blais, S ^a   Bercelli, P ^a   Lombrail, P ^a  

^a Registre des cancers de Loire Atlantique et de Vendée ^*  (France)

^b Structure de gestion du dépistage organisé en Loire Atlantique   (France)

Author keywords

Breast; Cancer; Incidence; Organised screening program; Staging

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER REGISTRY; CANCER SCREENING; CARCINOMA IN SITU; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FRANCE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PROGNOSIS; REGISTRIES;

EID: 40849119788     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respe.2008.01.001     Document Type: Article

References (31)

1. Remontet L., Esteve J., Bouvier A.M., Grosclaude P., Launoy G., Menegoz F., et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 51 (2003) 3-30
2. Bossard N., Velten M., Remontet L., Belot A., Maarouf N., Bouvier A.M., et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43 (2007) 149-160
3. Botha J.L., Bray F., Sankila R., and Parkin D.M. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 39 (2003) 1718-1729
4. Tyczynski JE, Bray F, Parkin DM. Breast cancer in Europe. ENCR Fact sheets 2002;2:1-4.
5. Fédération nationale des Centres de lutte contre le cancer. Comprendre le cancer du sein. Guide d'information et de dialogue à l'usage des patientes et de leurs proches. SOR 2002:1-164.
6. Engel J., Eckel R., Kerr J., Schmidt M., Furstenberger G., Richter R., et al. The process of metastasisation for breast cancer. Eur J Cancer 39 (2003) 1794-1806
7. Grosclaude P., Colonna M., Hédelin G., Trétarre B., Arveux P., Mace Lesec'h J., et al. Survival of women with breast cancer in France: variation with age, stage and treatment. Breast Cancer Res Treat 70 (2001) 137-143
8. Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjold B., and Rutqvist L.E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 (2002) 909-919
9. Nystrom L., Rutqvist L.E., Wall S., Lindgren A., Lindqvist M., Ryden S., et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341 (1993) 973
10. Tabar L., Fagerberg C.J., Gad A., Baldetorp L., Holmberg L.H., Grontoft O., et al., Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1 (1985) 829-832
11. Tabar L., Yen M.F., Vitak B., Chen H.H., Smith R.A., and Duffy S.W. Mammography service screening and mortality in breast cancer patients:20-year follow-up before and after introduction of screening. Lancet 361 (2003) 1405-1410
12. Paty AC, Ancelle-Park R, Bloch J. Dépistage des cancer du sein. Rapport d'évaluation du suivi épidémiologique. Données 2004. Institut National de Veille Sanitaire, mai 2007.
13. Schaffer P., Renaud R., Gairard B., and Guldenfels C. Le rôle des registres de cancer dans l'évaluation des campagnes de dépistage du cancer du sein. Rev Epidemiol Sante Publique 44 Suppl. 1 (1996) S15-S21
14. Buiatti E., Barchielli A., Bartolacci S., Federico M., De Lisi V., Bucchi L., et al. The impact of organised screening programmes on the stage-specific incidence of breast cancer in some Italian areas. Eur J Cancer 39 (2003) 1776-1782
15. e ed. (1998), Springer-Verlag, France, Paris
16. Exbrayat C., Garnier A., Colonna M., Assouline D., Salicru B., Winckel P., et al. Analysis and classification of interval cancers in a French breast cancer screening programme (departement of Isere). Eur J Cancer Prev 8 (1999) 255-260
17. Ganry O., Peng J., and Dubreuil A. Evaluation du dépistage de masse du cancer du sein dans le département de la Somme (France) entre 1990 et 1996. Rev Epidemiol Sante Publique 47 (1999) 335-341
18. Groupe collaboratif : structures de gestion du dépistage réseau français des registres de cancers Francim, centres de lutte contre le cancer, Institut de Veille sanitaire. Estimation de l'impact du dépistage organisé sur la mortalité par cancer du sein. Contexte, méthodologie et faisabilité. Institut de Veille Sanitaire, mars 2007.
19. Remontet L, Buemi A, Velten M, Jougla E, Estève J. Évolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. Institut de Veille Sanitaire, septembre 2002.
20. Lacour A., Mamelle N., Arnold F., et al. Les programmes de dépistage de masse du cancer du sein en France. J Gynecol Obstet Biol Reprod (Paris) 26 (1997) 470-483
21. Menegoz F., Exbrayat C., Sousbie M., Laforet C., Colonna M., Veran-Peyret M.F., et al. Patterns of health care delivery and breast cancer in the department of Isere in 1995. Rev Epidemiol Sante Publique 47 (1999) 443-453
22. Harmer C., Staples M., and Kavanagh A.M. Evaluation of breast cancer incidence: is the increase due entirely to mammographic screening?. Cancer Causes Control 10 (1999) 333-337
23. Cutuli B., Cottu P.H., Guastalla J.P., Mechin H., Costa A., and Jourdan R. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients. Breast Cancer Res Treat 95 (2006) 55-64
24. Schootman M., Jeffe D., Reschke A., and Aft R. The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Breast Cancer Res Treat 85 (2004) 219-222
25. Anderson W.F., Jatoi I., and Devesa S.S. Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943-2002). Breast Cancer Res Treat 99 (2006) 333-340
26. Coburn N.G., Chung M.A., Fulton J., and Cady B. Decreased breast cancer tumor size, stage, and mortality in Rhode Island: an example of a well-screened population. Cancer Control 11 (2004) 222-230
27. Kricker A., Farac K., Smith D., Sweeny A., McCredie M., and Armstrong B.K. Breast cancer in New South Wales in 1972-1995: tumor size and the impact of mammographic screening. Int J Cancer 81 (1999) 877-880
28. McCann J., Wait S., Seradour B., and Day N. A comparison of the performance and impact of breast cancer screening programmes in East Anglia, U.K. and Bouches du Rhone, France. Eur J Cancer 33 (1997) 429-435
29. Seradour B., Allemand H., and Schaffer P. Programme français de dépistage du cancer du sein. Résultats de cinq départements (1989-1994). Bull Cancer 84 (1997) 822-828
30. Ernst M.F., Roukema J.A., Coebergh J.W., Repelaer van Driel O.J., van Beek M.W., van der Sangen M.J., et al. Breast cancers found by screening: earlier detection, lower malignant potential or both?. Breast Cancer Res Treat 76 (2002) 19-25
31. Gill P.G., Farshid G., Luke C.G., and Roder D.M. Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 13 (2004) 15-22